RAC1 and non-small cell lung carcinoma: Of note, the use of a combination of PARP inhibitor and TKI leads to the inhibition of the RAC1/NADPH/ROS axis and the sensitization of the TKI-resistant NSCLC cell populations to apoptosis [12].